Indications
Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.
Composition
- Active substance
- laronidase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Aldurazyme
- Active substance
- laronidase
- ATC code
- A16AB05
- Therapeutic area
- Mucopolysaccharidosis I
- Marketing authorisation holder
- Sanofi B.V.
- Status
- Authorised